评估LBEC0101与依那西普参照品在甲氨蝶呤应答不佳的活动性类风湿关节炎患者中疗效与安全性相似性的III期、多中心、双盲、随机、平行组研究
这项III期多中心随机双盲平行组研究在日本和韩国开展,纳入374例甲氨蝶呤应答不佳的活动性类风湿关节炎患者,比较LBEC0101(依那西普生物类似药)与依那西普参照品的疗效与安全性。第24周DAS28-ESR较基线变化的最小二乘均值组间差异为-0.15(95%CI -0.377至0.078),落在预设等效界值-0.6至0.6内;两组ACR20应答率相似,不良事件发生率相当,LBEC0101组抗药抗体发生率较低。结论认为LBEC0101临床疗效与依那西普参照品等效,耐受性良好且安全性特征相当。
要点
- 第24周DAS28-ESR变化组间差异-0.15(95%CI -0.377至0.078)落在等效界值-0.6至0.6内。
- 第24周ACR20应答率LBEC0101组93.3% vs 依那西普参照品组86.7%。
- 至第54周不良事件发生率两组相当(92.0% vs 92.5%),抗药抗体发生率LBEC0101组1.6%低于参照品组9.6%。
核心结论
- LBEC0101的临床疗效与依那西普参照品等效。
- LBEC0101耐受性良好,安全性特征与依那西普参照品相当。
研究设计与样本
- III期、多中心、随机、双盲、平行组、54周研究,在日本和韩国开展。
- 共374例活动性类风湿关节炎且甲氨蝶呤应答不佳的患者随机分配至LBEC0101组(n=187)或依那西普参照品组(n=187)。
- 主要疗效终点为第24周基于红细胞沉降率的28关节疾病活动度评分(DAS28-ESR)较基线的变化。
主要发现
- 符合方案集第24周DAS28-ESR较基线变化的最小二乘均值:LBEC0101组-3.01(95%CI -3.198至-2.820),依那西普参照品组-2.86(95%CI -3.051至-2.667)。
- 组间差异估计值为-0.15(95%CI -0.377至0.078),落在预设等效界值-0.6至0.6内。
- 第24周ACR20应答率:LBEC0101组93.3% vs 依那西普参照品组86.7%。
- 至第54周不良事件发生率:LBEC0101组92.0% vs 依那西普参照品组92.5%。
- 抗药抗体发生率:LBEC0101组1.6% vs 依那西普参照品组9.6%。
关键数值与推荐
- 主要疗效等效性判定标准为DAS28-ESR变化组间差异的95%CI落在预设等效界值-0.6至0.6内。
- 第24周DAS28-ESR变化组间差异-0.15(95%CI -0.377至0.078)满足上述等效界值。
- 第24周ACR20应答率LBEC0101组93.3% vs 依那西普参照品组86.7%。
- 至第54周不良事件发生率LBEC0101组92.0% vs 依那西普参照品组92.5%。
- 抗药抗体发生率LBEC0101组1.6% vs 依那西普参照品组9.6%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the similarities between LBEC0101 (etanercept biosimilar) and the etanercept reference product (ETN-RP) in terms of efficacy and safety, including immunogenicity, in patients with active rheumatoid arthritis despite methotrexate treatment. METHODS: This phase III, multicentre, randomised, double-blind, parallel-group, 54-week study was conducted in Japan and Korea. The primary efficacy endpoint was the change from baseline in the disease activity score in 28 joints based on erythrocyte sedimentation rate (DAS28-ESR) at week 24. American College of Rheumatology 20% (ACR20) response rate, adverse events (AEs), pharmacokinetics and development of antidrug antibodies (ADAs) were also evaluated. RESULTS: In total, 374 patients were randomised to LBEC0101 (n=187) or ETN-RP (n=187). The least squares mean changes from baseline in DAS28-ESR at week 24 in the per-protocol set were -3.01 (95% CI -3.198 to -2.820) in the LBEC0101 group and -2.86 (95% CI -3.051 to -2.667) in the ETN-RP group. The estimated between-group difference was -0.15 and its 95% CI was -0.377 to 0.078, which was within the prespecified equivalence margin of -0.6 to 0.6. ACR20 response rates at week 24 were similar between the groups (LBEC0101 93.3% vs ETN-RP 86.7%). The incidence of AEs up to week 54 was comparable between the groups (LBEC0101 92.0% vs ETN-RP 92.5%), although fewer patients in the LBEC0101 group (1.6%) than the ETN-RP group (9.6%) developed ADAs. CONCLUSION: The clinical efficacy of LBEC0101 was equivalent to that of ETN-RP. LBEC0101 was well tolerated and had a comparable safety profile to ETN-RP. TRIAL REGISTRATION NUMBER: NCT02357069.
引用
- Matsuno H, Tomomitsu M, Hagino A, et al. Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate. Ann Rheum Dis. 2017. PMID: 29259050. doi:10.1136/annrheumdis-2017-212172
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。